Researchers discovered that tumors grow uniformly throughout their mass, challenging the idea of faster growth at edges.

Researchers at the University of Cologne and the Center for Genomic Regulation (CRG) in Barcelona have discovered that cancer ...

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress ...

HOUSTON -- Progression-free survival (PFS) in IDH -mutant low-grade glioma remained twice as high in adults who received ...

Cancer cells on the surface are thought to have natural advantages compared to cells deep within, which is why scientists have hypothesized tumors grow more in their periphery than in the core. A ...

Treatment with pimicotinib achieved a 54% objective response rate at 25 weeks vs 3.2% with placebo in patients with TGCT, ...

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York ...

Recent evidence underscores the pivotal role of communication between cancer and non-malignant cells within the tumor microenvironment (TME) in driving malignant progression. The TME, characterized by ...